Oscar Health (OSCR) Q2 2026 Earnings Call Transcript

Oscar Health reported Q2 2026 revenue of $4.9B (+70% YoY) and net income of $362M (+$590M YoY), with earnings from operations of $389M (8% operating margin) and a record-low SG&A expense ratio of 14.2% (-450 bps YoY). The medical loss ratio improved to 79.2% (about -12 pts YoY) aided by $164M favorable prior-period development and a $160M favorable CMS risk-adjustment report, and the company raised full-year earnings from operations guidance to $500M–$700M (+$250M vs prior outlook at the midpoint). Management reiterated full-year revenue guidance of $18.7B–$19.0B while warning CMS program integrity/eligibility verification may accelerate membership churn to closer to ~2% per month (vs prior 1–2%), though revenue impact is treated as timing/unenrollment vs fundamentals. Overall, profitability and operating leverage improved meaningfully, offsetting known regulatory churn risk.

Analysis

OSCR is the clearest near-term beneficiary: the business is showing rare operating leverage in a regulated insurance model, which should force the market to re-rate its unit economics rather than just its growth rate. The second-order implication is that competitors with older, multi-platform stacks now have to defend share while matching a lower-cost digital operating model; that typically shows up first as higher acquisition spend and then as margin pressure over 2-4 quarters.

The bigger structural story is ICHRA and portable coverage. If employers increasingly shift some populations into defined-contribution arrangements, OSCR can win both underwriting and distribution, while adjacent voluntary-benefit names like AFL and ALL get incremental channel value from marketplace participation rather than direct insurance spread. That said, the upside is not linear: the market is still early in the 2027 pricing cycle, and the company’s own commentary suggests the next leg depends on conversion friction, not just favorable demand.

Contrarian: the street may be too quick to capitalize one-quarter margin outperformance because part of the beat is non-recurring reserve and risk-adjustment timing. The true test is whether underlying MLR stays contained once the current membership mix seasons and CMS eligibility cleanup starts biting harder in the back half. If outpatient stays elevated or churn runs materially above plan, the current guide may prove more like a ceiling than a floor, which would cap multiple expansion after the initial pop.

Key Decisions for Investors

• Long OSCR on any post-earnings consolidation, with a 1-3 month horizon; thesis is further estimate revision as operating leverage shows through, but size modestly because part of the beat is timing-driven.
• Use a defined-risk call spread in OSCR for the 3-6 month window rather than outright stock if you want upside to 2027 enrollment/ICHRA adoption without full exposure to CMS churn risk.
• Set a sell/hedge trigger if OSCR’s underlying MLR trends above ~82.5%-83% ex prior-period development or if membership churn accelerates faster than management’s back-half assumptions; that would signal the margin story is peaking.
• Watch AFL and ALL as secondary beneficiaries of marketplace/voluntary-benefit distribution; they are not direct underwriting winners, but they can gain incremental embedded access if portable coverage adoption keeps building.